| Modulation of anxiety through blockade of anandamide hydrolysis S Kathuria, S Gaetani, D Fegley, F Valiño, A Duranti, A Tontini, M Mor, ... Nature medicine 9 (1), 76-81, 2003 | 1482 | 2003 |
| Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy HY Frank, M Mantegazza, RE Westenbroek, CA Robbins, F Kalume, ... Nature neuroscience 9 (9), 1142-1149, 2006 | 858 | 2006 |
| An endocannabinoid mechanism for stress-induced analgesia AG Hohmann, RL Suplita, NM Bolton, MH Neely, D Fegley, R Mangieri, ... Nature 435 (7045), 1108-1112, 2005 | 739 | 2005 |
| Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis G Gobbi, FR Bambico, R Mangieri, M Bortolato, P Campolongo, M Solinas, ... Proceedings of the National Academy of Sciences 102 (51), 18620-18625, 2005 | 665 | 2005 |
| Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide … D Fegley, S Gaetani, A Duranti, A Tontini, M Mor, G Tarzia, D Piomelli Journal of Pharmacology and Experimental Therapeutics 313 (1), 352-358, 2005 | 434 | 2005 |
| Pharmacological profile of the selective FAAH inhibitor KDS‐4103 (URB597) D Piomelli, G Tarzia, A Duranti, A Tontini, M Mor, TR Compton, O Dasse, ... CNS drug reviews 12 (1), 21-38, 2006 | 354 | 2006 |
| Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress M Bortolato, RA Mangieri, J Fu, JH Kim, O Arguello, A Duranti, A Tontini, ... Biological psychiatry 62 (10), 1103-1110, 2007 | 316 | 2007 |
| Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism JR Clapper, G Moreno-Sanz, R Russo, A Guijarro, F Vacondio, A Duranti, ... Nature neuroscience 13 (10), 1265-1270, 2010 | 293 | 2010 |
| Cyclohexylcarbamic acid 3 ‘-or 4 ‘-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure− activity relationships, and … M Mor, S Rivara, A Lodola, PV Plazzi, G Tarzia, A Duranti, A Tontini, ... Journal of medicinal chemistry 47 (21), 4998-5008, 2004 | 291 | 2004 |
| Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus JK Makara, M Mor, D Fegley, SI Szabó, S Kathuria, G Astarita, A Duranti, ... Nature neuroscience 8 (9), 1139-1141, 2005 | 244 | 2005 |
| Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation C Solorzano, C Zhu, N Battista, G Astarita, A Lodola, S Rivara, M Mor, ... Proceedings of the National Academy of Sciences 106 (49), 20966-20971, 2009 | 201 | 2009 |
| Design, synthesis, and structure− activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors G Tarzia, A Duranti, A Tontini, G Piersanti, M Mor, S Rivara, PV Plazzi, ... Journal of medicinal chemistry 46 (12), 2352-2360, 2003 | 188 | 2003 |
| A catalytically silent FAAH-1 variant drives anandamide transport in neurons J Fu, G Bottegoni, O Sasso, R Bertorelli, W Rocchia, M Masetti, A Guijarro, ... Nature neuroscience 15 (1), 64-69, 2012 | 185 | 2012 |
| The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice R Russo, J LoVerme, G La Rana, TR Compton, J Parrott, A Duranti, ... Journal of Pharmacology and Experimental Therapeutics 322 (1), 236-242, 2007 | 181 | 2007 |
| The Hippo pathway and YAP/TAZ–TEAD protein–protein interaction as targets for regenerative medicine and cancer treatment: Miniperspective M Santucci, T Vignudelli, S Ferrari, M Mor, L Scalvini, ML Bolognesi, ... Journal of medicinal chemistry 58 (12), 4857-4873, 2015 | 119 | 2015 |
| 2-[N-Acylamino(C1−C3)alkyl]indoles as MT1 Melatonin Receptor Partial Agonists, Antagonists, and Putative Inverse Agonists G Spadoni, C Balsamini, A Bedini, G Diamantini, B Di Giacomo, A Tontini, ... Journal of medicinal chemistry 41 (19), 3624-3634, 1998 | 117 | 1998 |
| L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC M Bersanelli, R Minari, P Bordi, L Gnetti, C Bozzetti, A Squadrilli, ... Journal of thoracic oncology 11 (10), e121-e123, 2016 | 113 | 2016 |
| URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices AR King, A Duranti, A Tontini, S Rivara, A Rosengarth, JR Clapper, ... Chemistry & biology 14 (12), 1357-1365, 2007 | 110 | 2007 |
| Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice J LoVerme, A Duranti, A Tontini, G Spadoni, M Mor, S Rivara, N Stella, ... Bioorganic & medicinal chemistry letters 19 (3), 639-643, 2009 | 102 | 2009 |
| Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties G Astarita, B Di Giacomo, S Gaetani, F Oveisi, TR Compton, S Rivara, ... Journal of Pharmacology and Experimental Therapeutics 318 (2), 563-570, 2006 | 99 | 2006 |
Giorgio TarziaHonorary Professor, Medicinal Chemistry, University of UrbinoVerified email at uniurb.it
